home / stock / kura / kura news

KURA News and Press, Kura Oncology Inc. From 12/08/23

Stock Information
Company Name: Kura Oncology Inc.
Stock Symbol: KURA
Market: NASDAQ
Website: kuraoncology.com
Menu
KURA KURA Quote KURA Short KURA News KURA Articles KURA Message Board
Get KURA Alerts

News, Short Squeeze, Breakout and More Instantly...
KURA - Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood can...
KURA - Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, ...

KURA - Kura Oncology, Inc. (KURA) Q3 2023 Earnings Call Transcript

2023-11-03 16:12:08 ET Kura Oncology, Inc. (KURA) Q3 2023 Earnings Conference Call November 02, 2023 04:30 PM ET Company Participants Pete De Spain - Head of Investor Relations Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice Presiden...

KURA - Kura Oncology files for $150M common stock offering, mixed securities shelf

2023-11-03 08:02:08 ET More on Kura Oncology Kura Oncology, Inc. 2023 Q3 - Results - Earnings Call Presentation Kura's Ziftomenib: The Swiss Army Knife In AML Therapy Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript Kura Oncology GAAP EPS of -$0.50...
KURA - Kura Oncology GAAP EPS of -$0.50 beats by $0.05

2023-11-02 16:29:30 ET More on Kura Oncology Kura's Ziftomenib: The Swiss Army Knife In AML Therapy BofA starts Kura at buy, cites revenue potential of lead drug ziftomenib Seeking Alpha’s Quant Rating on Kura Oncology Historical earnings data for Kura...

KURA - Kura Oncology Reports Third Quarter 2023 Financial Results

– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarter of 2024 – – Fi...

KURA - Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRAS?¹²?-Mutated NSCLC

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology com...
KURA - Expected US Company Earnings on Thursday, November 2nd, 2023

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

KURA - Expected earnings - Kura Oncology Inc.

Kura Oncology Inc. (KURA) is expected to report $-0.56 for Q3 2023

KURA - Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, ...
Previous 10 Next 10